Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Targeting connexin 43 with α–connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1

Figure 2

Reduced proliferation of MCF7 and MDA MB 231 cells treated with ACT1. (A) MCF7 cells were treated with vehicle or R-pep (200 μM) for 48 hours and assessed for total cell number. (B) MCF7 cells were treated for 48 hours with 50, 100, or 200 μM of R-pep or ACT1 and total cell number were compared at each drug concentration. (C) MDA MB 231 cells were treated with vehicle or R-pep (200 μM) for 48 hours and assessed for total cell number. (D) MDA MB 231 cells were treated for 48 hours with 50, 100, or 200 μM of R-pep or ACT1 and total cell number were compared at each drug concentration. Student’s T-test analysis was used to determine statistical significance. *p < 0.01; ± SEM; n = 8.

Back to article page